Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch + Lomb to Hold Investor Day on Nov. 13
04:30pm, Monday, 03'rd Nov 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on T
Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results
07:45am, Friday, 31'st Oct 2025
Bausch Health Companies delivered strong Q3 results, with revenue up 6.8% year-over-year and EPS beating estimates by $0.10. BHC's growth is driven by successful product launches like Cabtreo, robust
BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales
11:30am, Thursday, 30'th Oct 2025
Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.
Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript
08:26pm, Wednesday, 29'th Oct 2025
Bausch Health Companies Inc. ( BHC ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Garen Sarafian - VP & Head of Investor Relations Thomas Appio - CEO & Director Jean-Jacques
Bausch Health Announces Third Quarter 2025 Results
04:05pm, Wednesday, 29'th Oct 2025
Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $179
Critical Analysis: Pathfinder Bancorp (NASDAQ:PBHC) vs. TFS Financial (NASDAQ:TFSL)
02:36am, Sunday, 26'th Oct 2025
Pathfinder Bancorp (NASDAQ: PBHC - Get Free Report) and TFS Financial (NASDAQ: TFSL - Get Free Report) are both finance companies, but which is the better stock? We will compare the two companies base
Bausch Health (BHC) Expected to Beat Earnings Estimates: Should You Buy?
11:08am, Wednesday, 22'nd Oct 2025
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health Companies (TSE:BHC) Shares Up 4.5% – Time to Buy?
02:17am, Tuesday, 21'st Oct 2025
Bausch Health Companies Inc. (TSE: BHC - Get Free Report)'s share price shot up 4.5% during trading on Monday. The company traded as high as C$8.96 and last traded at C$8.87. 291,768 shares traded han
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb
10:57am, Monday, 20'th Oct 2025
Activist investor Jana Partners has reportedly taken a stake in The Cooper Companies (NASDAQ:COO) and is pressing the medical-device maker to evaluate strategic alternatives — including a potential
Bausch Health Announces Results of Special Meeting of Shareholders
07:00am, Thursday, 09'th Oct 2025
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
08:00am, Tuesday, 30'th Sep 2025
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful a
Bausch Health to Announce Third Quarter 2025 Results on October 29
07:00am, Tuesday, 30'th Sep 2025
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
08:00am, Monday, 29'th Sep 2025
Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K.
Bausch Health: Repricing Continues As Deleveraging Gains Traction
12:04pm, Thursday, 11'th Sep 2025
Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, impr
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
08:35am, Thursday, 11'th Sep 2025
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV
